 |
Title
|
|
|
|
Phase 
|
|
|
|
Protocol IDs
|
|
|
| |
Erlotinib and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
|
|
|
|
Phase II, Phase I
|
|
|
|
VU-VICC-GI-0622
VICC-GI-0622, 6980, NCI-6980, NCT00397384
|
|
| |
Evaluation of Single Session Stereotactic Body Radiotherapy
|
|
|
|
Phase II, Phase I
|
|
|
|
2005-0445
NCT00492817
|
|
| |
Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)
|
|
|
|
Phase II, Phase I
|
|
|
|
ID02-446
NCT00508443
|
|
| |
CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma
|
|
|
|
Phase II, Phase I
|
|
|
|
2007-0248
NCT00634751
|
|
| |
Peripheral Stem Cell Transplant and White Blood Cell Transfusions in Treating Patients With Refractory Metastatic Solid Tumors
|
|
|
|
Phase II
|
|
|
|
NHLBI-99-H-0064
NCT00003839
|
|
| |
Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder
|
|
|
|
Phase II
|
|
|
|
FCCC-03042
6135, NCI-6135, NCT00085410
|
|
| |
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
|
|
|
|
Phase II
|
|
|
|
NCI-04-C-0273
NCI-6332, DELCATH-G990039, NCT00096083
|
|
| |
Lapatinib in Treating Patients With Unresectable Liver or Biliary Tract Cancer
|
|
|
|
Phase II
|
|
|
|
OSU-0447
6696, NCI-6696, NCT00107536
|
|
| |
Bevacizumab and Erlotinib in Treating Patients With Metastatic or Unresectable Biliary Tumors
|
|
|
|
Phase II
|
|
|
|
MAYO-MC044G
7024, NCI-7024, NCT00356889
|
|
| |
Study to Test the Benefit and Safety of DAVANAT in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer
|
|
|
|
Phase II
|
|
|
|
DAVFU-007
NCT00386516
|
|
